文献速递中毒与环境急症儿科与产科急症

6岁及以下儿童速释曲马多暴露:法国全国中毒控制中心研究

Exposure to immediate-release tramadol in children 6 years and under - a nationwide French poison control center study.
PubMed 文献 · Clin Toxicol (Phila) · 2022-02-18
一句话结论6岁及以下儿童单独摄入<7.4 mg/kg速释曲马多且无基础疾病及合并用药者可居家观察,但需警告家长惊厥风险。

该研究回顾性分析2003-2019年法国中毒控制中心收集的1260例≤6岁儿童速释曲马多暴露,其中145例单独摄入速释曲马多。中位年龄3.0岁,中位剂量5.0 mg/kg。49.7%无症状,29.6%出现轻度、14.5%出现中重度神经系统症状,12例出现呼吸抑制,无惊厥和死亡,所有症状儿童24小时内恢复。摄入剂量与中毒严重度评分正相关(p<.0001)。ROC曲线分析显示摄入≥7.4 mg/kg适合建议住院转诊。作者认为无基础疾病且无合并用药的儿童单独摄入<7.4 mg/kg可居家观察,但需警告惊厥风险。

要点

  • 145例单独摄入速释曲马多的≤6岁儿童中,49.7%无症状,29.6%轻度、14.5%中重度神经系统症状,12例呼吸抑制,无惊厥和死亡。
  • 摄入剂量与中毒严重度评分正相关(p<.0001);ROC曲线下面积0.92(p<.001)。
  • 摄入≥7.4 mg/kg速释曲马多适合建议住院转诊(敏感性100%[95%CI 85-100],特异性73%[95%CI 64-80])。
  • 摄入<7.4 mg/kg的儿童仅出现无(n=68)或轻度(n=22)神经系统症状。
  • 作者认为无基础疾病且无合并用药、单独摄入<7.4 mg/kg速释曲马多的儿童可居家观察,但需警告家长惊厥风险。

适用人群与场景

  • ≤6岁儿童经口暴露于速释曲马多,数据来自法国中毒控制中心2003-2019年收集的病例。
  • 单独摄入速释曲马多的145例儿童纳入分析,中位年龄3.0岁(IQR 1.9-4.0),男女比1.5。
  • 作者结论中提及无基础疾病且无合并用药的儿童可居家观察,适用于单独摄入<7.4 mg/kg速释曲马多者。

诊断标准与关键阈值

  • 采用中毒严重度评分(PSS)分级:PSS0为无症状,PSS1为轻度,PSS2-PSS3为中重度。
  • ROC曲线分析确定摄入≥7.4 mg/kg速释曲马多适合建议住院转诊(曲线下面积0.92,p<.001)。

处置流程与药物剂量

  • 摄入≥7.4 mg/kg速释曲马多:建议住院转诊(敏感性100%[95%CI 85-100],特异性73%[95%CI 64-80],阳性预测值39%[95%CI 35-57],阴性预测值100%[95%CI 96-100])。
  • 作者认为无基础疾病且无合并用药、单独摄入<7.4 mg/kg速释曲马多的儿童可居家观察。
  • 作者建议向家长或监护人特别警告曲马多摄入后惊厥风险,惊厥可在摄入剂量低于7.4 mg甚至治疗剂量时发生。

红旗征与不能漏的情况

  • 摄入速释曲马多后出现呼吸抑制:145例中12例发生。
  • 惊厥风险:作者指出曲马多摄入后惊厥发生时间存在变异性,可在摄入剂量低于7.4 mg甚至治疗剂量时发生,需警告家长。

研究设计与关键结果

  • 回顾性分析法国中毒控制中心2003-2019年收集的1260例≤6岁儿童速释曲马多暴露,其中145例单独摄入速释曲马多进行分析。
  • 每10万例接受速释曲马多治疗患者中的病例数随时间增加(p<.0001)。
  • 145例中位摄入剂量5.0 mg/kg(IQR 3.3-11.1);49.7%无症状(PSS0),29.6%轻度(PSS1),14.5%中重度(PSS2-PSS3)神经系统症状;12例出现呼吸抑制;无惊厥和死亡;所有症状儿童24小时内恢复。
  • 摄入剂量与PSS正相关(p<.0001);ROC曲线下面积0.92(p<.001),摄入≥7.4 mg/kg适合建议住院转诊(敏感性100%[95%CI 85-100],特异性73%[95%CI 64-80],阳性预测值39%[95%CI 35-57],阴性预测值100%[95%CI 96-100])。
  • 摄入<7.4 mg/kg的儿童出现无(n=68)或轻度(n=22)神经系统症状。

证据类型、等级与局限

  • 研究类型:回顾性分析,数据来自法国中毒控制中心2003-2019年收集的病例。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为无基础疾病且无合并用药、单独摄入<7.4 mg/kg速释曲马多的≤6岁儿童可居家观察。
  • 作者建议对摄入速释曲马多的儿童家长或监护人特别警告惊厥风险,因惊厥可在低于7.4 mg甚至治疗剂量时发生。
  • 摄入≥7.4 mg/kg速释曲马多适合建议住院转诊(基于ROC曲线分析)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Data regarding immediate-release (IR)-tramadol exposures in children remain sparse. We aimed to investigate the incidence of IR-tramadol exposures in ≤6-year-old children, to describe the characteristics and resulting outcome of ingestions involving IR-tramadol alone, and to estimate a clinically relevant toxic dose in this population.

METHODS: Retrospective analysis of IR-tramadol exposures in ≤6-year-old children, collected by the French Poison Control Centers (PCCs) in 2003-2019. The incidence was estimated using IR-tramadol prescription data from the Health Improvement Network database (the French version of THIN). The Poison severity score (PSS) was used to grade severity.

RESULTS: We found 1260 IR-tramadol exposures in ≤6-year-old children. The number of cases per 100,000 IR-tramadol-treated patients increased over time (p < .0001). One hundred forty-five cases involving IR-tramadol alone were analyzed. The median age was 3.0 years (IQR: 1.9, 4.0), the M/F ratio was 1.5 and the median dose was 5.0 mg/kg (IQR 3.3-11.1). Half of the children (49.7%) remained asymptomatic (PSS0) while 29.6% and 14.5% developed minor (PSS1) or moderate-to-severe (PSS2-PSS3) neurological symptoms, respectively. Twelve children developed respiratory depression. No seizures and no fatality were reported. All symptomatic children recovered within 24 h. The ingested IR-tramadol dose was positively correlated with the PSS (p < .0001). Using a receiver operating characteristic (ROC) curve approach (area under the curve, 0.92; p < .001), ingestion of ≥7.4 mg/kg IR-tramadol was appropriate to recommend hospital referral (sensitivity, 100% [95% confidence interval (CI), 85-100]; specificity, 73% [95% CI, 64-80]; predictive positive value, 39% [95% CI, 35-57]; negative predictive value, 100% [95% CI, 96-100]). Children who ingested <7.4 mg/kg IR-tramadol developed no (n = 68) or minor (n = 22) neurological symptoms.

CONCLUSIONS: Despite increasing tramadol prescriptions in adults during the study period in France, oral exposure to IR-tramadol in ≤6-year-old children was rare but possibly responsible for severe toxicity. Children with no underlying disease and concomitant medication ingesting <7.4 mg/kg IR-tramadol alone could be observed at home. However, given the observed variability in the onset of seizures after tramadol ingestion, which can occur at ingested tramadol doses below 7.4 mg and even at therapeutic doses, parents or guardians should be specifically warned about the risk of seizures.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Caré W, Tangre A, Dufayet L, et al. Exposure to immediate-release tramadol in children 6 years and under - a nationwide French poison control center study. Clin Toxicol (Phila). 2022. PMID: 35179098. doi:10.1080/15563650.2022.2033257

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。